Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC
April 8th 2022Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.
Read More
Multidisciplinary, Virtual Endocrinology Care Improves Outcomes in Diabetes
April 8th 2022This new study evaluated the impact of a virtual endocrinology care program on time in range and outcomes among individuals with poorly controlled diabetes who are novice users of continuous glucose monitoring.
Read More
Dr Bernice Kwong Discusses Impact of Delayed Diagnosis, Treatment for GVHD
April 8th 2022Bernice Kwong, MD, clinical professor of dermatology, Stanford University, talks about how later diagnosis and treatment for graft-versus-host disease (GVHD) affects disease progression and overall patient outcomes.
Watch
Dr Robert Sidbury Discusses Impact of New AAD Guidelines on Atopic Dermatitis Treatment
April 8th 2022Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, discussed how new guidelines issued by the American Academy of Dermatology (AAD) regarding comorbidity risk in patients with atopic dermatitis will influence the condition's treatment.
Watch
Formulary Placement Led to Delays, Disruptions in Receiving Sacubitril/Valsartan for CHF
April 8th 2022More than a quarter of patients experience disruptions and delays in treatment for chronic heart failure (CHF) after the initial prescription for sacubitril/valsartan was abandoned/rejected.
Read More
Several Factors Contribute to Impaired Fertility in Women, Men With CKD
April 8th 2022A literature review outlined the number of fertility complications that men and women with chronic kidney disease (CKD) face as well as the list of potential factors that can impact fertility and sexual functions in this population.
Read More
European Study Shows High Rate of Skin Conditions, Diseases
April 8th 2022When including patients who had a mole check or cancer screening, the proportion of patients with at least 1 dermatological condition or disease increased to 47%; both non-melanoma and melanoma skin cancers were among the top 12 skin diseases reported in the study.
Read More
Nearly One-Fourth of DLBCL Cases May Be Attributable to Obesity in Young Adulthood, Says Study
April 8th 2022Across all measures, researchers found that body mass index in young adults had the strongest association with the risk of non-Hodgkin lymphoma (NHL), estimating that 23.3% of diffuse large B-cell lymphoma (DLBCL) cases and 11% of NHLs overall can be attributed to obesity.
Read More
What We’re Reading: Medicare Coverage of Aduhelm; US Life Expectancy Drops; Pandemic-Induced Trauma
April 8th 2022CMS issues final plan for aducanumab (Aduhelm) coverage; 2021 sees further drop in US life expectancy; individuals have presented with symptoms of trauma throughout the COVID-19 pandemic.
Read More
Older EoE Patients More Likely to Respond to Topical Corticosteroids, Study Finds
April 8th 2022Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.
Read More
Genomic Profiling Utility for Targeted Therapy Selection Shown in Advanced GI Cancers
April 8th 2022The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.
Read More
Equivalent Safety, Efficacy Between Herceptin and Trastuzumab Biosimilar for Gastric Cancer
April 7th 2022A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Read More
Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product
April 7th 2022Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Watch
Incremental Steps Helpful but Not Enough to End Underinsurance Issue, Panelists Say
April 7th 2022Without addressing rising costs, the problem of underinsurance in health care coverage will remain, said panelists at the 2022 V-BID Summit, discussing some of the smaller steps that are being proposed or are already in place to try to ease the financial burden.
Read More
Higher DKA Rates Seen in Black Patients With T1D Throughout COVID-19
April 7th 2022Compared with other racial/ethnic groups, Black patients with type 1 diabetes (T1D) presented to medical centers with diabetic ketoacidosis (DKA) more often throughout the COVID-19 pandemic, regardless of COVID-19 infection.
Read More
Dr Stephen Rozzo on Regulatory Nature of Tildrakizumab for Psoriasis
April 7th 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, explains tildrakizumab’s mechanisms of action in the treatment of psoriasis and how the drug differs from other approved biologics.
Watch
Increasing Health Equity to Reduce Disparities in Value-Based Care
April 7th 2022At the 2022 V-BID Summit, hosted by the Center for Value-Based Insurance Design at the University of Michigan, representatives of CMS and the Commonwealth Fund gave an update on the efforts to monitor, evaluate, and improve health equity in the United States.
Read More
What We’re Reading: Variant-Specific Boosters; CDC Revamp; EPA Asbestos Ban
April 7th 2022A panel of experts advised the FDA to support the development of COVID-19 variant-specific booster doses; the CDC is undergoing a month-long review in efforts to revamp the agency; the Environmental Protections Agency (EPA) proposed a rule to ban asbestos.
Read More